Synthesis of polyamines from ethylenediamine and their platinum(II) complexes, potential antitumor agents

This work describes the synthesis and characterization of five new amine ligands and also the preparation and characterization of their respective platinum(II) complexes by reaction with K2PtCl4 in water. These ligands were obtained by treatment of different halides or epoxides with ethylenediamine. Cytotoxic activity and cellular accumulation of three complexes were investigated in a human small-cell lung carcinoma cell line and its cisplatin resistant subline. The introduction of a spacer (cycle) between the two platinum atoms leads to a significant decrease in cytotoxic activity. At equitoxic doses, the intracellular platinum concentrations found for compounds 12 and 15 were significantly higher than those found for the reference compounds, cisplatin, carboplatin, or compound 9. This fact suggests that the formation of adducts between compounds 12 and 15 and the putative pharmacological target, DNA, is less favored. If these compounds bind more slowly to DNA, interaction with other intracellular ligands such as sulfur-containing molecules will become relevant and it may be the reason for the elevated intracellular platinum concentrations. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)

[1]  P. Morin,et al.  Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[2]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[3]  A. Garnier-Suillerot,et al.  Synthesis, characterization, cytotoxic activity, and cellular accumulation of dinuclear platinum complexes derived from N,N'-di-(2-aminoethyl)-1,3-diamino-2-propanol, aryl substituted N-benzyl-1,4-butanediamines, and N-benzyl-1,6-hexanediamines. , 2003, Journal of inorganic biochemistry.

[4]  A. Garnier-Suillerot,et al.  Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin , 2003, JBIC Journal of Biological Inorganic Chemistry.

[5]  Jerry Goodisman,et al.  Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[6]  T. Thomas,et al.  Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications , 2001, Cellular and Molecular Life Sciences CMLS.

[7]  M. V. Almeida,et al.  Synthesis of platinum complexes from N-benzyl ethylenediamine derivatives , 2000 .

[8]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[9]  T. Hambley.  The influence of structure on the activity and toxicity of Pt anti-cancer drugs , 1997 .

[10]  Y. Zou,et al.  Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformational changes in DNA. , 1995, Biochemistry.

[11]  A. Pegg,et al.  Spermidine/spermine N1‐acetyltransferase — the turning point in polyamine metabolism , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  F. Muggia,et al.  Platinum resistance: Laboratory findings and clinical implications , 1993, Stem cells.

[13]  M. L. Edwards,et al.  Synthesis and DNA-binding properties of polyamine analogues. , 1991, Journal of medicinal chemistry.

[14]  J. Moulinoux,et al.  Erythrocyte polyamine levels in human prostatic carcinoma. , 1990, The Journal of urology.

[15]  N. Farrell,et al.  Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. , 1990, Journal of medicinal chemistry.

[16]  G. F. Davis,et al.  Polyamine analogues with antitumor activity. , 1990, Journal of medicinal chemistry.

[17]  John D. Roberts,et al.  Interaction of novel bis(platinum) complexes with DNA. , 1989, Nucleic acids research.

[18]  E. de Vries,et al.  Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. , 1988, Cancer research.

[19]  N. Farrell,et al.  Bis(platinum) complexes containing two platinum cis-diammine units. Synthesis and initial DNA-binding studies , 1988 .

[20]  A. Pegg,et al.  Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. , 1988, Cancer research.

[21]  F. Zunino,et al.  New Cisplatin Analogues—On the Way to Better Antitumor Agents , 1987 .

[22]  C. Porter,et al.  Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. , 1986, Anticancer research.

[23]  D. Lydall,et al.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.

[24]  K. Beaumont,et al.  Platinum complexes of substituted ethylenediamines and their anti-tumour activity. , 1976, Chemico-biological interactions.

[25]  J. Leboul,et al.  Some ring-opening reactions of a diepoxide derived from (-)-quinic acid. , 1971, Carbohydrate research.

[26]  D. Russell.  Increased polyamine concentrations in the urine of human cancer patients. , 1971, Nature: New biology.

[27]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.